Author

Barbara R Snyder

Observed names: B Snyder, B.R. Snyder

Institution: University of Nebraska Medical Center

Observed institutions: Onconova Therapeutics (United States), University of Nebraska Medical Center

OpenAlex ID: A5006012748

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

2019 · Ofri Mosenzon, Thalia Marie Blicher, et al. · The Lancet Diabetes & Endocrinology · 349

112 Randomized Phase Iii Study of Iv Rigosertib Versus Best Supportive Care (bsc) in Patients With Higher-risk Mds (hr-mds) After Failure of Hypomethylating Agents (hmas)

2015 · G. Garcia-Manero, P. Fenaux, et al. · Leukemia Research · 2

Correlation of overall survival (OS) with bone marrow blast (BMBL) response in patients (pts) with myelodysplastic syndrome.

2015 · Lewis R. Silverman, Pierre Fenaux, et al. · Journal of Clinical Oncology · 1

INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs)—Study design informed by subgroup analyses of ONTIME.

2016 · Guillermo Garcia-Manero, Aref Al-Kali, et al. · Journal of Clinical Oncology

111 Mutational Profile and Karyotypic Abnormalities of Clinical Trial Patients With Higher-risk Mds Following Failure of Hypomethylating Agents (hmas): Impact on Response to Rigosertib Therapy

2015 · G.J. Mufti, S. Best, et al. · Leukemia Research

Works count: 5

Citation count: 352

H-index: 2

I10-index: 1